The Latest Breaking News from Eli Lilly

With the market searching for a bottom, Tesla, Microsoft, Eli Lilly and other leading stocks try to recharge as May kicks off.

A cardiologist who helped invent an automatic implantable defibrillator that has helped countless heart patients live longer and healthier has died

Eli Lilly And Co (NYSE:LLY) reported topline results from SURMOUNT-1 Phase 3 trial evaluating Tirzepatide (5 mg, 10 mg, 15 mg) in obese patients with at least one comorbidity who do not have diabetes. Data exhibited that tirzepatide reduced patients' weights by an average of 16%, 21.4%, and 22.5% at the respective doses,…

Eli Lilly And Co (NYSE:LLY) has posted Q1 sales of $7.8 billion, beating the consensus of $6.68 billion. Lilly's revenue increased 15%, driven by volume growth of 20%, partially offset by a 3% decrease due to lower realized prices and a 2% decrease due to the unfavorable impact of foreign exchange rates. …

Eli Lilly and Company's (NYSE:LLY) short percent of float has fallen 12.05% since its last report. The company recently reported that it has 5.79 million shares sold short, which is 0.73% of all regular shares that are available for trading.

While earnings were mainly higher, the U.S. economy shrank in the first quarter.

Eli Lilly topped first-quarter expectations and raised its sales outlook for 2022, prodding LLY stock to pop Thursday.

The Dow finishes up 600 points as the tech sector helps markets rebound from heavy losses.

  Eli Lilly (NYSE:LLY) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:25 AM. Here's what investors need to know about the announcement.